Antibiotics Archives

RedHill pill shows promise vs Omicron; mRNA vaccines appear effective in those with well-controlled HIV

Antibiotics, Antiretroviral Therapy, BNT162b2 (Pfizer and BioNTech), Coronavirus Vaccines, COVID-19 Studies, COVID-19 treatment pill, Gilead, HIV, Hospitalized COVID-19 Patients, JAMA, Messenger RNA (mRNA) Vaccines, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), R&D, Remdesivir, Steroids

An experimental drug being developed by RedHill Biopharma Ltd. that improved outcomes in a randomized trial involving severely ill COVID-19 patients infected with earlier versions of the coronavirus is showing promise against the Omicron variant in test tube experiments, researchers said. Additionally, people living with well-controlled HIV infections are likely to have immune responses to the mRNA COVID-19 vaccines from Moderna and from Pfizer/BioNTech similar to those of otherwise healthy individuals, according to new data.

April 11, 2022/by Reuters Health

Reuters Health

Pharma Industry-Backed Fund Invests in Two Biotech Companies to Treat ‘Superbugs’

Antibiotic resistance, Antibiotics, Business, Investments, R&D, R&D, Research & Development, Startups, Superbugs, Superbugs

A $1 billion fund backed by over 20 drugmakers made its first set of investments on April 4 in two biotechnology startups, nearly two years after it was launched to help struggling antibiotic makers tackle the threat of antibiotic-resistant bacteria.

April 4, 2022/by Reuters Health

Venatorx Scores Victory over AMR in Phase III UTI Study

Antibiotics, Cephalosporins, Clinical Trials, Complicated Urinary Tract Infections (cUTI), Fast Track Designation, R&D

Venatorx Pharmaceuticals shared that the company’s Phase III trial on the investigational treatment for complicated urinary tract infections in adults delivered positive outcomes.

March 10, 2022/by Andrew Humphreys

Over 1.2 million people died from drug-resistant infections in 2019 – study

Antibiotics, Deaths, Drug-resistant bacteria, R&D, Respiratory infections, Studies

More than 1.2 million people died in 2019 from infections caused by bacteria resistant to multiple antibiotics, higher than HIV/AIDS or malaria, according to a new report published on January 20.

January 20, 2022/by Reuters Health

Klick Health and Lakeridge Health Unveil Free Drug Dosage Calculator to Fight Antibiotic-Resistant Bacterial Infections

Antibiotics, Bacterial Infections, Collaborations, Google, Healthcare Communications Agencies, Innovation, Marketing & Advertising, Moderna, Pharmacists, Physicians

Klick Health and Lakeridge Health introduced a technologically advanced medication dosage calculator to help pharmacists and physicians determine the correct amount of vancomycin for treating life-threatening, antibiotic-resistant, bacterial infections.

August 4, 2021/by Andrew Humphreys

Four Pharma Companies Debut on Nasdaq

Antibiotics, Biopharma, Business, Clinical Trials, Clostridium difficile, Collaboration, FDA, Financing, Gaucher Disease, Gene Editing, Initial Public Offering (IPO), Nasdaq, R&D, Series B, Shares, Sickle Cell Disease, Solid Tumors, Stocks

In a flurry of activity, multiple biopharma companies made their first appearance on the Nasdaq Stock Exchange on June 25, raising hundreds of millions of dollars to advance the development of next-generation therapeutics and scale their businesses.

June 25, 2021/by Andrew Humphreys

Boehringer Ingelheim Launches Weight-Loss Trials for NASH

Antibiotic resistance, Boehringer Ingelheim, Business, Clinical Trials, Glucagon, Glucagon-Like Peptide-1 (GLP-1) Analogs, Infusions, Lyme Disease, Non-alcoholic steatohepatitis (NASH), Obesity, Overweight, Partnerships, R&D

Germany’s Boehringer Ingelheim partnered with Denmark’s Zealand Pharma A/S to study the GLP-1/glucagon dual agonist BI 456906 in two Phase II trials as a potential treatment for adults who are overweight or obese and for adults with non-alcoholic steatohepatitis (NASH).

April 15, 2021/by Andrew Humphreys

Antibiotics in development not enough to tackle ‘superbugs’ – WHO

Antibiotic resistance, Antibiotics, Antimicrobial Resistance (AMR), Antimicrobials, AstraZeneca, Bacterial Infections, Bristol Myers Squibb, Drug Classes, Novartis, R&D, Superbugs, Therapeutics, World Health Organization

None of the 43 antibiotics in development as well as recently approved medicines are enough to combat the increasing emergence and spread of antimicrobial resistance, the World Health Organization cautioned on April 15.

April 15, 2021/by Andrew Humphreys

Immuno-Oncology Treatments Finding Success with Combination Therapies

Antibiotics, Blockbusters, Bristol Myers Squibb, Business, Clinical Trials, Collaborations, Combination Therapies, Immune System, Immuno-oncology, Melanoma, Metastatic Breast Cancer, Metastatic Melanoma, Pfizer, Progression-Free Survival (PFS), R&D, Therapeutics, Tumors

In the RELATIVITY-047 Phase II/III trial combining Bristol Myers Squibb’s Opdivo with the anti-LAG-3 antibody relatlimab, the drug mashup met the study’s primary goal for progression-free survival compared to use of the blockbuster brand alone in metastatic melanoma patients.

March 25, 2021/by Andrew Humphreys

Antibiotics may have been overused in Covid-19 patients: U.S. study

Antibiotics, Bacterial Infections, Coronavirus Disease (COVID-19) Pandemic, Covid-19 Data, COVID-19 Studies, Hospitalized COVID-19 Patients, Pneumonia, Superbugs, Urinary Tract Infections (UTI)

A majority of Covid-19 patients that were admitted to U.S. hospitals during the first few months of the pandemic were prescribed antibiotics even before a bacterial infection had been confirmed, a study showed on March 10.

March 10, 2021/by Andrew Humphreys